Amundi’s Pliant Therapeutics PLRX Stock Holding History

Amundi’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-138	Closed	-$181	–	2049
2025 Q1	$181	Buy	138 +86	+165%	+$522	﹤0.01%	2165
2024 Q4	$656	Buy	+52	New	+$710	﹤0.01%	2078

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Amundi's PLRX Position: Q2 2025 in Review

Amundi sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 138 shares — an estimated $181 sold.

Amundi first reported a position in PLRX in Q4 2024 and held it in 2 quarters. The position peaked at $656 in Q4 2024. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

Amundi reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
Amundi sold 138 Pliant Therapeutics shares in Q2 2025, an estimated $181.
Amundi first reported a position in Pliant Therapeutics in Q4 2024 and held it in 2 quarters.
Amundi's Pliant Therapeutics position peaked at $656 in Q4 2024.
114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.